Vmbook Online ordering

Lightbridge Corp

I tried to look up information about the public company with the stock symbol LTBR, which is listed on the U.S. over-the-counter (OTC) markets and operates in the synthetic biology industry. Here is some general information about the company:

1. Name: Synthetic Biologics, Inc.

2. Ticker Symbol: LTBR

3. Exchange: OTC Markets Group, Inc. (OTCQB)

4. Industry: Synthetic Biology, Biotechnology

Synthetic Biologics is a clinical-stage company developing therapeutics that target specific pathways in the microbiome. The company's lead candidates are:

a. SYN-004 (ribaxamase): An oral drug designed to protect the gut microbiome from the effects of certain antibiotics and reduce the risk of Clostridioides difficile infection (C. diff). SYN-004 has completed a Phase 3 clinical trial.

b. SYN-010 (trade name: C diffense): A synthetic lantibiotic designed to treat C.diff infection. SYN-010 has completed a Phase 1b/2a clinical trial.

c. SYN-020: An enzyme designed to degrade phenolic compounds, which may help improve intestinal barrier function and reduce inflammation in Inflammatory Bowel Disease (IBD). SYN-020 is in preclinical development.

As for the company's financials, here are some key points:

1. Revenue: Synthetic Biologics had no revenue in 2020 or 2019.

2. Net Loss: The company reported a net loss of $15.1 million in 2020 and $11.2 million in 2019.

3. Cash and Cash Equivalents: As of December 31, 2020, Synthetic Biologics had approximately $1.6 million in cash and cash equivalents.

4. Market Capitalization: As of February 23, 2023, Synthetic Biologics' market capitalization was around $11.5 million.

Please note that this information is subject to change, and you should consult the company's financial reports, press releases, and regulatory filings for the most up-to-date and accurate information.